Literature DB >> 2642995

Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis.

U Specks1, C L Wheatley, T J McDonald, M S Rohrbach, R A DeRemee.   

Abstract

Sixty-five patients with biopsy-proven Wegener's granulomatosis (WG), 54 with systemic vasculitis, 22 with relapsing polychondritis, 20 with sarcoidosis, 20 with malignant pulmonary lesions, and 15 with other conditions underwent determination of anticytoplasmic autoantibodies (ACPA) by the indirect immunofluorescence technique on neutrophil cytospin preparations to assess the specificity of ACPA for WG, their sensitivity in relationship to the extent and activity of the disease, and their value for follow-up of WG. Of these 65 patients with WG, 38 were ACPA positive. Two patients in the vasculitis group, best categorized as having microscopic polyarteritis, were ACPA positive. We obtained 125 serum samples from the 65 patients with WG and assigned them to one of two categories (limited or generalized), based on the extent of disease. Each of these categories was then subdivided into "active" or "in remission." Median ACPA titers were significantly different between active disease and remission in each category, as well as between active limited and active generalized disease. All patients whose disease changed from active to in remission had reductions in ACPA titer levels; those who experienced flares had titer increases. Patients with intercurrent illnesses or complications of treatment, mimicking WG flares, did not have titer increases. We conclude that ACPA determined by the indirect immunofluorescence technique is highly specific for WG. The sensitivity is dependent on the extent and activity of WG, and serial titer determinations are valuable in monitoring disease activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642995     DOI: 10.1016/s0025-6196(12)65300-2

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  26 in total

Review 1.  Clinical value of antineutrophil cytoplasmic antibodies.

Authors:  V Rus; B S Handwerger
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  The current status of neutrophil cytoplasmic antibodies.

Authors:  F J van der Woude; M R Daha; L A van Es
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

Review 4.  The ANCA test: its clinical relevance.

Authors:  G Ramírez; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

Review 5.  Significance of antibodies to cytoplasmic components of neutrophils.

Authors:  U Specks; R A DeRemee
Journal:  Thorax       Date:  1989-05       Impact factor: 9.139

6.  Anti-neutrophil cytoplasmic autoantibodies in a child with pauci-immune necrotizing and crescentic glomerulonephritis.

Authors:  L A Baldree; L W Gaber; C P McKay
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

7.  Detection of anti-myeloperoxidase and anti-elastase antibodies in vasculitides and infections.

Authors:  M C Gallicchio; J A Savige
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

Review 8.  Antineutrophil cytoplasmic antibody--a useful serological marker for vasculitis.

Authors:  J A Goeken
Journal:  J Clin Immunol       Date:  1991-07       Impact factor: 8.317

9.  Antineutrophil antibodies (ANCA)

Authors:  C Feighery; J Jackson
Journal:  Ir J Med Sci       Date:  1991-03       Impact factor: 1.568

Review 10.  Vasculitis in childhood.

Authors:  I Roberti; L Reisman; J Churg
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.